Lexicon Pharmaceuticals, Inc. announced on September 4, 2025, the presentation of new preclinical data at the 9th International Congress on Neuropathic Pain (NeuPSIG) 2025. The data demonstrated pilavapadin's ability to reduce neuropathic pain in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS).
These findings highlight the relevance of inhibiting pilavapadin's novel target, AAK1, for the modulation of pain signaling. The results suggest potential for pilavapadin in additional neuropathic pain indications beyond diabetic peripheral neuropathic pain (DPNP).
Pilavapadin is a potent, once-daily, orally delivered, selective investigational small molecule inhibitor of AAK1. This expansion of potential therapeutic areas could broaden the future market opportunity for the drug.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.